Regimens of Intermittent Occlusion Therapy for Amblyopia in Children

NCT ID: NCT02767856

Last Updated: 2022-07-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to answer the question: What if the Intermittent Occlusion (IO-therapy) glasses were prescribed all day (12-hours) in which the total time of treatment only took 4 weeks instead of the current treatment time (4 hours) in which it takes 12 weeks?

Children aged 3- to 8-years with untreated moderate unilateral amblyopia will be enrolled and randomized into 2 groups: 1) Intense 12-hour IO-therapy Group for 4 weeks treatment; or 2) Standard 4-hour IO-therapy glasses Group for 12 weeks treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amblyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intense 12-hour IO-therapy Group

Participants wear 12-hour daily IO-therapy glasses for 4 weeks

Group Type EXPERIMENTAL

IO-therapy Glasses

Intervention Type DEVICE

Standard 4-hour IO-therapy Group

Participants wear 4-hour daily IO-therapy glasses for 12 weeks

Group Type ACTIVE_COMPARATOR

IO-therapy Glasses

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IO-therapy Glasses

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The following criteria must be met for the patient to be enrolled in the study:

1. Age 3 to \< 8 years
2. Unilateral amblyopia associated with strabismus (comitant or incomitant), anisometropia, or both

Criteria for strabismus: At least one of the following criteria must be met:
* Heterotropia at distance and/or near fixation on examination (with or without spectacles)
* History of strabismus surgery
* Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia)

Criteria for anisometropia: At least one of the following criteria must be met:
* \>0.50 D difference between eyes in spherical equivalent
* \>0.50 D difference between eyes in astigmatism in any meridian
3. Amblyopic eye has no myopia (\> -0.25 D spherical equivalent).
4. Visual acuity, measured in each eye without cycloplegia within 7 days prior to enrollment using the ATS single-surround HOTV letter protocol as follows:

* Visual acuity in the amblyopic eye between 20/40 and 20/80 inclusive
* Visual acuity in the sound eye 20/32 or better
* Inter-eye acuity difference ≥ 2 logMAR lines (i.e., amblyopic eye acuity at least 2 lines worse than sound eye acuity)
5. No previous amblyopia treatment within 6 months.
6. Spectacle correction (if applicable) for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction within 6 months:

* Requirements for spectacle correction:
* For patients meeting criteria for only strabismus

* Hypermetropia if corrected must not be undercorrected by more than +1.50 D spherical equivalent, and the reduction in plus sphere must be symmetric in the two eyes. Otherwise, spectacle correction is at investigator discretion.
* For patients meeting criteria for anisometropia or combined-mechanism

* Spherical equivalent must be within 0.50 D of fully correcting the anisometropia
* Hypermetropia must not be undercorrected by more than +1.50 D spherical equivalent, and reduction in plus must be symmetric in the two eyes
* Cylinder power in both eyes must be within 0.50 D of fully correcting the astigmatism
* Cylinder axis in the spectacle lenses in both eyes must be within 6 degrees of the axis of the cycloplegic refraction

Spectacles meeting above criteria must be worn either:
* for 4 weeks immediately prior to enrollment, or
* until visual acuity in amblyopic eye is stable (defined as two consecutive visual acuity measurements at least 4 weeks apart with no improvement of one line or more)
* An acuity measurement done any of the following ways may be considered the first of two consecutive measurements:

* in current glasses,
* in trial frames with full correction of hypermetropia with cycloplegia, or
* in new glasses.
7. Wearing optimal spectacle correction for a minimum of 4 weeks at the time of enrollment.
8. Ocular examination within 6 months prior to enrollment.
9. Gestational age \> 34 weeks and birth weight \> 1500 grams
10. Parent willing to accept randomization
11. Parent willing to be contacted and has access to phone
12. Parent does not anticipate relocation outside area within study period.

Exclusion Criteria

1. Amblyopic eye has myopia worse than -3.00 D spherical equivalent.
2. Prior intraocular or refractive surgery
3. Ocular pathologies that impact vision
4. Cognitive impairment that prohibits accurate data collection
Minimum Eligible Age

3 Years

Maximum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Salus University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Salus University

Elkins Park, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Wang J, Malik A, Jin J, Pang Y, Yin K, Allen M, Grigorian A, Scombordi B, Bailey J, Aljohani S, Funari K, Shoge R, Meiyeppen S, Myung J, Soni A, Neely DE. Intense versus standard regimens of intermittent occlusion therapy for unilateral moderate amblyopia in children: study protocol for a randomized controlled trial. Trials. 2020 Apr 28;21(1):361. doi: 10.1186/s13063-020-04284-4.

Reference Type DERIVED
PMID: 32345348 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HJW1604

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Enhancement of Emmetropization in Hyperopic Infants
NCT00574717 TERMINATED PHASE1/PHASE2
Binocularly Balanced Viewing Study
NCT03754153 COMPLETED NA